Grufity logoGrufity logo
StocksFundsSearch Filings

Amedisys Inc Stock Research

AMED

77.31USD+0.56(+0.73%)Delayed

Market Summary

USD77.31+0.56
Delayed
0.73%

AMED Stock Price

AMED RSI Chart

AMED Valuation

Market Cap

2.5B

Price/Earnings (Trailing)

22.43

Price/Sales (Trailing)

1.13

EV/EBITDA

14.07

Price/Free Cashflow

24.19

AMED Price/Sales (Trailing)

AMED Profitability

EBT Margin

7.21%

Return on Equity

11.28%

Return on Assets

6%

Free Cashflow Yield

4.13%

AMED Fundamentals

AMED Revenue

Revenue (TTM)

2.2B

Revenue Y/Y

2.04%

Revenue Q/Q

-1.01%

AMED Earnings

Earnings (TTM)

112.2M

Earnings Y/Y

-20.29%

Earnings Q/Q

-20.4%

Price Action

52 Week Range

69.45131.32
(Low)(High)

Last 7 days

-2.6%

Last 30 days

0.9%

Last 90 days

-15.8%

Trailing 12 Months

-34.1%

AMED Financial Health

Current Ratio

1.09

Debt/Equity

0.4

Debt/Cashflow

0.32

AMED Investor Care

Buy Backs (1Y)

0.07%

Diluted EPS (TTM)

3.44

Peers (Alternatives to Amedisys)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
73.0B
60.9B
-4.91% 25.24%
12.73
1.2
1.94% -15.77%
20.7B
14.8B
-2.77% -13.32%
16.22
1.39
-6.96% -52.35%
15.0B
9.6B
-8.90% -4.59%
18.89
1.56
-10.08% -57.84%
MID-CAP
9.9B
13.6B
-10.37% 3.84%
14.64
0.74
5.04% -26.87%
8.1B
2.2B
-3.35% 8.33%
33.85
3.75
1.03% -10.38%
5.2B
2.3B
3.17% 35.63%
86.23
2.28
2.85% -58.05%
5.0B
3.2B
-11.17% 9.89%
21.14
1.55
17.88% 19.62%
3.9B
4.8B
11.84% 2.65%
10.12
0.8
3.57% -4.88%
2.9B
482.2M
34.10% -27.10%
-4.41
5.98
23.29% -70.12%
2.5B
2.2B
0.86% -34.14%
22.43
1.13
0.55% -41.23%
SMALL-CAP
1.7B
1.5B
6.01% 44.82%
-126.07
1.14
10.24% -173.11%
1.4B
976.1M
-21.09% 3.91%
28.65
1.47
10.19% 12.37%
919.4M
1.1B
3.90% -11.21%
51.63
0.85
-2.36% -86.62%
394.4M
146.1M
-12.69% 63.35%
63.38
2.84
20.87% -35.06%

Financials for Amedisys

Income Statement (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Revenue0.5%2,2342,2232,2202,2162,222
  S&GA Expenses1.7%736724---
Costs and Expenses0.8%2,0592,0422,0382,0151,996
EBITDA-3.0%207214235298-
EBITDA Margin-3.1%0.09*0.10*0.11*0.13*-
Earnings Before Taxes-5.6%151160166187256
EBT Margin-3.5%0.07*0.07*0.08*0.12*-
Interest Expenses19.5%27.0022.0019.0017.0011.00
Net Income-5.4%112119121140191
Net Income Margin-2.0%0.05*0.05*0.06*0.09*-
Free Cahsflow38.0%12792.00167178-
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Assets-1.5%1,9471,9761,9822,0011,908
  Current Assets4.3%406389389395392
    Cash Equivalents70.4%69.0041.0018.0027.0068.00
  Net PPE108.5%33.0016.0017.0018.0017.00
  Goodwill-3.3%1,2451,2871,2851,2909.00
Liabilities-6.4%814870913962888
  Current Liabilities-0.7%353356367427380
  Long Term Debt-11.0%373419443442429
Shareholder's Equity7.8%1,1331,0521,0161,0391,021
  Retained Earnings3.3%783758726700671
  Additional Paid-In Capital0.5%759755751743737
Accumulated Depreciation3.7%10510110210099.00
Shares Outstanding0.1%33.0033.0032.0032.0033.00
Minority Interest-1.4%54.0055.0054.0053.0054.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q12022Q42022Q32022Q22022Q1
Cashflow From Operations-17.0%11113398.00173184
  Share Based Compensation-24.6%12.0017.0022.0023.0024.00
Cashflow From Investing65.6%-32.51-94.49-104-367-296
Cashflow From Financing-162.6%-79.92-30.43-90.03151105
  Buy Backs-46.4%17.0032.0043.0027.00-

Risks for AMED

What is the probability of a big loss on AMED?

73.1%


Probability that Amedisys stock will be more than 20% underwater in next one year

36.5%


Probability that Amedisys stock will be more than 30% underwater in next one year.

33.5%


Probability that Amedisys stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does AMED drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Amedisys was unfortunately bought at previous high price.

Drawdowns

Returns for AMED

Cumulative Returns on AMED

19.7%


10-Year Cumulative Returns

6.2%


7-Year Cumulative Returns

0.7%


5-Year Cumulative Returns

-25.7%


3-Year Cumulative Returns

What are the long-term rolling returns for AMED?

FIve years rolling returns for Amedisys.

Annualized Returns

Which funds bought or sold AMED recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-05-23
Capital Impact Advisors, LLC
reduced
-33.37
-233,989
332,078
0.41%
2023-05-23
Front Row Advisors LLC
unchanged
-
-
2,000
-%
2023-05-23
Seaport Global Advisors, LLC
added
12.37
-2,017
186,449
0.59%
2023-05-23
Toroso Investments, LLC
new
-
478,000
478,000
0.01%
2023-05-22
FDx Advisors, Inc.
unchanged
-
-
231,000
0.01%
2023-05-22
AMERIPRISE FINANCIAL INC
reduced
-24.99
-30,716,200
59,729,800
0.02%
2023-05-18
NEW YORK STATE COMMON RETIREMENT FUND
added
8.57
-181,000
3,918,000
-%
2023-05-18
JPMORGAN CHASE & CO
added
13.48
-139,000
146,881,000
0.02%
2023-05-17
Sunbelt Securities, Inc.
new
-
5,823
5,823
-%
2023-05-17
Advisory Services Network, LLC
unchanged
-
-7,702
56,708
-%

1–10 of 45

Latest Funds Activity

Are funds buying AMED calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own AMED
No. of Funds

Amedisys News

Home Health Care News
'We See The Long-Term Value': BofA, JPMorgan And Others Weigh ....
Home Health Care News,
21 hours ago
Seeking Alpha
Stockhouse Publishing
Hospice News
Home Health Care News

Schedule 13G FIlings of Amedisys

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 18, 2023
flynn james e
5.51%
1,794,000
SC 13G
Feb 14, 2023
ameriprise financial inc
3.39%
1,100,719
SC 13G/A
Feb 09, 2023
vanguard group inc
9.63%
3,128,416
SC 13G/A
Feb 06, 2023
wellington management group llp
8.63%
2,802,831
SC 13G/A
Jan 26, 2023
blackrock inc.
12.6%
4,106,566
SC 13G/A
Jan 20, 2023
blackrock inc.
12.6%
4,106,566
SC 13G
Jan 06, 2023
jpmorgan chase & co
5.4%
1,763,327
SC 13G
Feb 14, 2022
ameriprise financial inc
5.35%
1,742,916
SC 13G
Feb 09, 2022
vanguard group inc
9.69%
3,158,777
SC 13G/A
Feb 04, 2022
wellington management group llp
5.56%
1,812,411
SC 13G/A

AMED Fair Value

Amedisys fair value in different scenarios

The table shows the Fair Value estimates for Amedisys for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

57.59

-25.51%

70.52

-8.78%

90.91

17.59%

121.81

57.56%

139.69

80.69%
Current Inflation

53.76

-30.46%

64.93

-16.01%

82.14

6.25%

108.07

39.79%

123.02

59.13%
Very High Inflation

48.98

-36.64%

58.09

-24.86%

71.66

-7.31%

92.01

19.01%

103.69

34.12%

Historical Amedisys Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Amedisys

View All Filings
Date Filed Form Type Document
May 26, 2023
425
Prospectus Filed
May 26, 2023
425
Prospectus Filed
May 18, 2023
425
Prospectus Filed
May 18, 2023
SC 13G
Major Ownership Report
May 17, 2023
425
Prospectus Filed
May 15, 2023
425
Prospectus Filed
May 15, 2023
425
Prospectus Filed
May 15, 2023
425
Prospectus Filed
May 15, 2023
425
Prospectus Filed
May 10, 2023
425
Prospectus Filed

Latest Insider Trading transactions for AMED

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-05-03
Samuels Ivanetta Davis
acquired
-
-
1,941
-
2023-05-03
Klapstein Julie D
acquired
-
-
1,941
-
2023-05-03
PERKINS BRUCE D
acquired
-
-
1,941
-
2023-05-03
Rideout Jeffrey A
acquired
-
-
1,941
-
2023-05-03
CAPPS VICKIE L
acquired
-
-
1,941
-
2023-05-03
Coye Molly Joel
acquired
-
-
1,941
-
2023-05-03
Kline Teresa L.
acquired
-
-
1,941
-
2023-04-12
Ashworth Richard M
acquired
-
-
46,982
president and ceo
2023-04-10
Kusserow Paul B. K.
sold (taxes)
-1,282,350
78.88
-16,257
-
2023-03-03
North Michael Paul
sold
-510,628
86.43
-5,908
chief information officer

1–10 of 50

Christopher T. Gerard
21000
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The Personal Care segment provides assistance for patients with the activities of daily living. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care and palliative care to patients in their homes. As of December 31, 2021, the company owned and operated 331 home health care centers, 175 hospice care centers, and 14 personal-care, and 8 high acuity care centers in 38 states within the United States and the District of Columbia. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.

AMED Income Statement

2023-03-31
CONSOLIDATED INCOME STATEMENT - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]  
Net service revenue$ 556,389$ 545,257
Cost of service, inclusive of depreciation315,010304,820
General and administrative expenses:  
Salaries and benefits126,339123,480
Non-cash compensation3,2737,347
Depreciation and amortization4,4438,008
Other64,94553,640
Total operating expenses514,010497,295
Operating income42,37947,962
Other income (expense):  
Interest income40613
Interest expense(7,517)(3,173)
Equity in earnings (loss) from equity method investments123(1,403)
Miscellaneous, net(682)333
Total other expense, net(7,670)(4,230)
Income before income taxes34,70943,732
Income tax expense(9,800)(12,019)
Net income24,90931,713
Net loss (income) attributable to noncontrolling interests337(42)
Net income attributable to Amedisys, Inc.$ 25,246$ 31,671
Basic earnings per common share:  
Net income attributable to Amedisys, Inc. common stockholders, basic (usd per share)$ 0.78$ 0.97
Weighted average shares outstanding, basic (shares)32,55832,555
Diluted earnings per common share:  
Net income attributable to Amedisys, Inc. common stockholders, diluted (usd per share)$ 0.77$ 0.97
Weighted average shares outstanding, diluted (shares)32,64332,766

AMED Balance Sheet

2023-03-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 49,436$ 40,540
Restricted cash19,66413,593
Patient accounts receivable294,122296,785
Prepaid expenses18,75411,628
Other current assets23,58126,415
Total current assets405,557388,961
Property and equipment, net of accumulated depreciation of $105,183 and $101,36433,35316,026
Operating lease right of use assets85,211102,856
Goodwill1,244,6791,287,399
Intangible assets, net of accumulated amortization of $16,071 and $14,60499,929101,167
Other assets78,23079,836
Total assets1,946,9591,976,245
Current liabilities:  
Accounts payable40,01743,735
Payroll and employee benefits122,723125,387
Accrued expenses137,899137,390
Current portion of long-term obligations26,95815,496
Current portion of operating lease liabilities25,45333,521
Total current liabilities353,050355,529
Long-term obligations, less current portion373,202419,420
Operating lease liabilities, less current portion59,82669,504
Deferred income tax liabilities22,75220,411
Other long-term obligations4,7814,808
Total liabilities813,611869,672
Commitments and Contingencies—Note 7 
Equity:  
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,938,354 and 37,891,186 shares issued; 32,544,145 and 32,511,465 shares outstanding3838
Additional paid-in capital758,669755,063
Treasury stock, at cost, 5,394,209 and 5,379,721 shares of common stock(462,508)(461,200)
Retained earnings782,918757,672
Total Amedisys, Inc. stockholders’ equity1,079,1171,051,573
Noncontrolling interests54,23155,000
Total equity1,133,3481,106,573
Total liabilities and equity$ 1,946,959$ 1,976,245